Novo Nordisk shares plunge 10% after Alzheimer's drug trial fails to hit key target
Shares of Novo Nordisk on Monday fell 10% after the Danish drug pharmaceutical company said a highly-anticipated trial for Alzheimer's disease failed to meet its main goal.
(CNBC, 2025-11-24T11:41:21Z)